Skip to main content
OpenTrials
Completed

NCT Number: NCT00999219

A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia

This study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) by polysomnography in patients with insomnia, excluding patients with schizophrenia or manic-depressive psychosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Chūbu, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is diagnosed as a primary insomnia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
  • Patients complaining of insomnia continuously for 4 weeks or longer
  • Patient's usual bedtime is between 9 p.m. and 12 a.m. for the 4 week period prior to initial screening
  • Patient on most occasions sleeps for a total of ≥3 and <6.5 hours over the 4 week period prior to initial screening
  • Patient's usual wake time after sleep onset in a single night is ≥45 minutes per night for the 4 week period prior to initial screening
  • Patients have a body weight of ≥45 kg and ≤85 kg, a BMI of ≥18.5 and <30

Exclusion criteria

  • Patients with schizophrenia or manic-depressive psychosis
  • Patients with insomnia caused by physical diseases including chronic obstructive pulmonary disease, bronchial asthma, fibrositis syndrome, chronic fatigue syndrome, rheumatic disease, climacteric disturbance, and dermatitis atopic
  • Patients with circadian rhythm sleep disorder
  • Patient works night shifts
  • Patients with alcoholic sleep disorder
  • Patients with alcohol or drug dependence or a history of these
  • Patients with insomnia related with drugs including antiparkinson, antihypertensive, or steroid drugs
  • Patients with sleep apnea syndrome
  • Patients with restless legs syndrome or periodic limb movement disorder
  • Patients with epileptic insomnia
  • Patients smoke on average 40 or more cigarettes a day
  • Patients who had received psychotropic drugs other than hypnotics (including anxiolytic or antidepressant drugs for hypnotic effect) within a 4 week period prior to the initial screening

Treatment and study plan

FK199B

Drug

oral

Other names: Zolpidem MR Tablet

zolpidem

Drug

oral

Other names: Myslee

Primary outcomes

  1. Sleep parameters estimated from polysomnography recording (wake time after sleep onset and number of awakenings)

    Time frame: 8 hours

Secondary outcomes

  1. Mean sleep parameters estimated from polysomnography recording

    Time frame: 8 hours

  2. Sleep parameters estimated from sleep questionnaire

    Time frame: After each night of sleep during the study period

  3. Patient impression from sleep questionnaire

    Time frame: After each night of sleep during the study period

Sponsors and collaborators

Lead sponsor

Astellas Pharma Inc

Industry

Registry information

Official study title

FK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Oct 21, 2009
Registry last updated
Aug 20, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.